https://www.pharmaradar360.com/article/df8a2c2b7cd408acPharma Surgeen2026-06-10T10:31:56.000ZCompany - Sellas Life Scienceshttps://www.pharmaradar360.com/article/4329d3d1643c3425Pharma Surgeen2026-06-10T03:00:00.000Z[IBENTO][IBENTO]Workshop on New Approach Methodologies (NAMs) Held following ICCR-20​https://www.pharmaradar360.com/article/325c6873bf0725d8Pharma Surgeen2026-06-10T02:30:00.000ZUpdate on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemiahttps://www.pharmaradar360.com/article/9d4fc7426a3911aaPharma Surgeen2026-06-09T22:18:00.000ZFDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitishttps://www.pharmaradar360.com/article/4216f81039e6b730Pharma Surgeen2026-06-09T20:30:12.000ZU.S. FDA Accepts Takeda sBLA for Review in Pediatric UC and Crohn’s Diseasehttps://www.pharmaradar360.com/article/801859f77000f7d7Pharma Surgeen2026-06-09T16:22:37.000ZJean-François Brochard élu Président du Leem et composition du nouveau Bureauhttps://www.pharmaradar360.com/article/c80d4e46b0cbb943Pharma Surgeen2026-06-09T16:13:43.000ZAcceso Pre-registro Asistencia Telemáticahttps://www.pharmaradar360.com/article/daa68cf3c1501774Pharma Surgeen2026-06-09T16:00:00.000ZInnovent submits NDA for CLDN18.2 ADC for gastric cancerhttps://www.pharmaradar360.com/article/c88f64ff9fcc09b5Pharma Surgeen2026-06-09T16:00:00.000ZNMPA gives conditional nods to drugs by Lupeng, Vcare, Staidsonhttps://www.pharmaradar360.com/article/7d7b7e5faa37410fPharma Surgeen2026-06-09T12:00:00.000ZGSK enters agreement to acquire Nuvalent, Inc.https://www.pharmaradar360.com/article/7d4cc6cdf93b3192Pharma Surgeen2026-06-09T12:00:00.000ZChina deals highlight biopharma evolution, reports LEKhttps://www.pharmaradar360.com/article/bfe3aa0539014dd3Pharma Surgeen2026-06-09T11:31:32.000ZPromotional material: National AI Commission: Ask Me Anythinghttps://www.pharmaradar360.com/article/62f59d59ddb2fd1bPharma Surgeen2026-06-09T10:41:05.000ZGuidance: AI Airlock Simulation Workshopshttps://www.pharmaradar360.com/article/e042e8b71b7377dePharma Surgeen2026-06-09T10:37:42.000ZGuidance: AI Airlock Sandbox Phase 2 Programme Reporthttps://www.pharmaradar360.com/article/6204144f8c50e3b7Pharma Surgeen2026-06-09T10:08:24.000ZΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 31 ΜΑΪΟΥhttps://www.pharmaradar360.com/article/884157d5592502edPharma Surgeen2026-06-09T09:59:21.000Zο ΕΟΦ είναι μέλος του Ευρωπαϊκού Δικτύου Ρυθμιστικών Αρχών Φαρμάκων (EMRN)https://www.pharmaradar360.com/article/cfc2b16fbc16b9d6Pharma Surgeen2026-06-09T07:46:00.000ZThe guidance on digital and decentralised clinical trials (DCT) has been updatedhttps://www.pharmaradar360.com/article/58e5f910a0ab273aPharma Surgeen2026-06-09T07:39:41.000ZRA Committee Townhall – How Agentic AI is Redefining Regulatory Excellencehttps://www.pharmaradar360.com/article/cb41d961f6a7a91cPharma Surgeen2026-06-09T06:00:08.000ZUN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)https://www.pharmaradar360.com/article/bfcb61eac3282003Pharma Surgeen2026-06-09T02:00:00.000ZPharmac to fund medicines used by ambulance providershttps://www.pharmaradar360.com/article/de1cd4223d7b4ba2Pharma Surgeen2026-06-09T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/5b945f6bb3137cbbPharma Surgeen2026-06-09T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/0e126fd9215b56cePharma Surgeen2026-06-09T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/d16d0abf0ae297edPharma Surgeen2026-06-09T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/9f991bda34984727Pharma Surgeen2026-06-09T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/962d9fa9d7dd472dPharma Surgeen2026-06-09T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/84563d1cd0ff04abPharma Surgeen2026-06-09T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/c658c7671c8f0311Pharma Surgeen2026-06-09T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/abeb351f0da8bc51Pharma Surgeen2026-06-09T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/bccec93bc17beb39Pharma Surgeen2026-06-09T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/2bb4a43449cd2136Pharma Surgeen2026-06-09T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/63b6fd5d13523fabPharma Surgeen2026-06-09T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/aba0d7dc2cadb4a2Pharma Surgeen2026-06-09T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/097414eacd628388Pharma Surgeen2026-06-09T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/74cb2281ea89d3b9Pharma Surgeen2026-06-09T00:00:00.000ZWhy Sleep Is Important for Brain Healthhttps://www.pharmaradar360.com/article/f2f7997dc3e086bfPharma Surgeen2026-06-09T00:00:00.000ZBausch Health, Canada Inc. et l’Alliance pancanadienne pharmaceutique concluent avec succès leurs négociations, menant à la signature d’une lettre d’intention pour OKEDI MC (suspension injectable à libération prolongée de rispéridone) dans le traitement de la schizophréniehttps://www.pharmaradar360.com/article/9e77384c46509b25Pharma Surgeen2026-06-09T00:00:00.000ZBausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of Pr OKEDI ® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia